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Abstract
BlaI is a repressor of BlaZ, the beta-lactamase responsible for penicillin resistance in Staph-
ylococcus aureus. Through screening a transposon library in S. aureus Newman for suscep-
tibility to cathelicidin antimicrobial peptide, we discovered BlaI as a novel cathelicidin
resistance factor. Additionally, through integrational mutagenesis in S. aureus Newman and
MRSA Sanger 252 strains, we confirmed the role of BlaI in resistance to human and murine
cathelidicin and showed that it contributes to virulence in human whole blood and murine
infection models. We further demonstrated that BlaI could be a target for innate immune-
based antimicrobial therapies; by removing BlaI through subinhibitory concentrations of 6-
aminopenicillanic acid, we were able to sensitize S. aureus to LL-37 killing.
Introduction
Staphylococcus aureus is a leading cause of community- and hospital-associated infections,
ranging from superficial syndromes to several potentially life-threatening invasive conditions
including sepsis and endocarditis [1]. Penicillin was once the drug of choice for treatment of S.
aureus infections. However, penicillin-resistant strains due to beta-lactamase production were
reported as early as 1942, and today over 95% of human S. aureus isolates are resistant to peni-
cillin [2]. The beta-lactamase-resistant penicillin derivate methicillin was introduced in 1961,
but the first methicillin-resistant S. aureus (MRSA) strains appeared shortly thereafter. Recent
reports of S. aureus isolates with intermediate or complete vancomycin resistance may fore-
shadow an era in which effective treatment of S. aureus infections may become extraordinarily
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Beta-lactamase-mediated penicillin resistance in S. aureus has been thoroughly investigated
[2]. The inducible S. aureus PC1 beta-lactamase is encoded by blaZ, and the transcription of
blaZ is controlled by the BlaZ-BlaR1-BlaI system [3,4]. The genes for BlaZ, its repressor BlaI
and the signal transducer-sensor protein BlaR1 are clustered together, either on a plasmid or
within the bacterial chromosome [5]. In the absence of beta-lactam exposure, the DNA repres-
sor BlaI represses blaZ by binding to the conserved DNA motif TACA/TGTA, located in the
promoter region of blaZ [6,7]. The detection of beta-lactam molecules by BlaR1 initiates a sig-
naling cascade, ultimately resulting in de-repression of blaZ (illustrated schematically in Fig
1A).
Antimicrobial peptides (AMPs) are fundamental components of mammalian innate immu-
nity to control microbial infections and coordinate host responses to infection. The AMPs
identified in humans include members of the cathelicidin, defensin, thromobicidin and histatin
families. The only cathelicidin found in humans is LL-37, while a functional homolog,
CRAMP, is present in mice. Bacterial pathogens have evolved countermeasures to decrease
their susceptibility to host AMPs including (i) decreased affinity to AMPs through cell enve-
lope modifications, (ii) active efflux pumps, (iii) external trapping of AMPs, (iv) production of
AMP degrading proteases, and (v) interference with host AMP production [8,9]. In the last sev-
eral years, it has been established that the degree of resistance to host AMPs correlates with the
potential of pathogenic bacteria to cause disease. Consequently, others and we have suggested
that AMP resistance factors could be targets for novel anti-bacterial drugs [10,11].
The work described in this paper provides evidence that S. aureus BlaI regulation extends
beyond the scope of beta-lactamase expression, and contributes in addition to the pathogen’s
resistance to cathelicidin AMPs. As a consequence, BlaI contributes to S. aureus innate
immune evasion and virulence. Pharmacological ablation of BlaI by low concentrations of
beta-lactams renders penicillin-resistant S. aureusmore susceptible to innate immune defenses.
This finding highlights a potential indirect utility of beta-lactam antibiotic treatment regimens
in treatment of MRSA infections.
Results
Inactivation of blaI Leads to Increased Cathelicidin Susceptibility in S.
aureus
To identify staphylococcal genes involved in cathelicidin resistance, a random mutant library
of S. aureus Newman was generated by Tn917 transposition. Individual mutants were screened
for increased susceptibility to the murine cathelicidin CRAMP. From 4,800 Tn917 mutants
screened, 19 showed>4-fold increased sensitivity to CRAMP as compared to the wild-type
(WT) strain. Putative CRAMP susceptible mutants identified in the primary screen were sub-
jected to additional testing to confirm their phenotype by characterizing (i) their susceptibility
to CRAMP in exponential and stationary phase and (ii) by demonstrating that the mutants
exhibited no replication defects in growth curves compared to the WT strain in Todd Hewitt
broth (THB; data not shown).
Five of the 19 CRAMP-hypersusceptible mutants mapped to varying locations within the
blaI gene. In one of these mutants (G2E3) the transposon insertion was mapped between base
pairs (bps) 12 and 13 of the beta-lactamase repressor gene blaI, which is part of the blaZ-
blaR1-blaI locus. The insertion of the transposon in the blaI gene was further confirmed by
PCRs with blaI and Tn917 specific primer pairs (data not shown). The blaZ-blaR1-blaI locus is
not found in the published chromosome sequence of S. aureus Newman [12] and thus must be
BlaI and S. aureusCathelicidin Resistance
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present in an extrachromosomal locus such as a plasmid. The organization of the blaZ-blaR1--
blaI locus for several S. aureus strains is well characterized [2] and was found to be the same in
S. aureus Newman as determined by PCRs. Fig 1B illustrates the organization of the blaZ-
blaR1-blaI locus in S. aureusNewman and the location of the Tn917 insertion in the cathelici-
din susceptible mutant G2E3. Of note, in sequenced S. aureus blaZ-blaR1-blaI loci such as that
of MRSA Sanger 252 (MRSA252) [5], blaR1 overlaps with the blaI gene by 11 bps. Thus, we
assumed that the transposon insertion in mutant G2E3 occurred 1 bp downstream of blaR1. Of
note, none of the CRAMP-hypersusceptible mutants mapped to the blaZ gene.
BlaI was confirmed as a cathelicidin resistance factor by targeted integrational mutagenesis
of blaI and in trans complementation of the resulting blaImutant strain in S. aureus Newman.
In addition, blaI was inactivated in MRSA252, in which the bla operon is located on the bacte-
rial chromosome [5]. The beta-lactamase activities of both genetically engineered blaImutant
strains were compared to those of the respective wildtype (WT) strains using nitrocefin as the
test reagent. The WT strains showed significant beta-lactamase activity in the presence of the
beta-lactam nitrocefin as compared to the medium only controls. Disruption of the beta-lacta-
mase repressor blaI led to ~twofold elevated beta-lactamase (BlaZ) activity in both S. aureus
Newman and MRSA252 blaImutant strains (Fig 1C). The complemented Newman blaI strain
also demonstrated increased beta-lactamase activity, inferring that BlaI activity may not be
completely restored in that strain upon plasmid complementation (data not shown). As
expected, a MRSA252 blaZmutant completely lacked activity in the nitrocefin test confirming
functional inactivation of the beta-lactamase BlaZ (data not shown).
Fig 1. Mapping of the Tn917mutant and subsequent inactivation of blaI leading to elevated beta-
lactamase production. (A) (1) In the absence of beta-lactams, the blaZ-blaR1-blaI genes are repressed by
BlaI. (2) When beta-lactammolecules are sensed by BlaR1, the cytoplasmatic domain of this transmembrane
protein is autoproteolytically cleaved. (3) Following this event, the repressor protein BlaI is proteolytically
cleaved and dissociates from its binding site, enabling transcription of the beta-lactamase-encoding gene
blaZ. (4) Finally, the active beta-lactamase BlaZ is secreted, leading to hydrolysis of the beta-lactam
molecules. (B) Organization of the blaZ-blaR1-blaI locus in S. aureusNewman. blaR1 and blaI are located in a
two-gene operon. blaZ is divergently transcribed. In the cathelicidin susceptible S. aureusNewmanmutant
G2E3, Tn917 integration occurred 12 bp downstream of the blaI start codon. (C) S. aureusNewmanWT and
blaImutant or MRSA252WT and blaImutant were incubated with 50 μg/ml nitrocefin for 30 min at 37°C, and
the absorbance at 490 nm (A490) was read. A higher A490 value reflects higher beta-lactamase activity. Mean
A490 values ± SD of duplicates of one representative experiment of at least three performed for each strain
are shown. ***, p<0.001. A representative picture for the MRSA252WT and blaImutant bacteria after
incubation with nitrocefin are shown.
doi:10.1371/journal.pone.0136605.g001
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Additionally, we tested the minimum inhibitory concentration (MIC) [13] of penicillin G
against the strains as a second readout of beta-lactamase activity. Compared to the WT strains,
we observed a slight, but reproducible increase in the MICs of blaImutants in both the New-
man (64 μg/ml for WT vs.128 μg/ml for blaImutant) and MRSA252 (64 μg/ml for WT vs.
128 μg/ml for blaImutant) backgrounds. The complemented Newman blaI strain had an MIC
similar to the mutant (128 μg/ml), additional evidence that BlaI activity may not be
completely restored. These results indicated that the expression of the beta-lactamase BlaZ was
de-repressed through inactivation of the blaZ repressor BlaI. Furthermore, to determine if BlaI
played a role in resistance to the anti-staphylococcal antibiotic daptomycin, we tested the sus-
ceptibility of the Newman strains using a standard Etest. The blaI strain had a slightly
decreased MIC (0.125 μg/ml) compared to the WT (0.250 μg/ml) and complemented mutant
(0.250 μg/ml) strains.
We next performed killing kinetics with cathelicidin AMPs. Compared to their respective S.
aureus Newman and MRSA252 WT strains, the blaImutants were found to be more suscepti-
ble to the murine cathelicidin CRAMP and human LL-37 with their CFU concentrations being
approximately 0.5 logs lower compared to the respective WT strains after 1–2 hours of co-incu-
bation with the cathelicidins (Fig 2A–2D). The difference in AMP susceptibility between the
Newman and MRSA252 WT and their respective blaImutants was observed for both station-
ary and exponential phase cells (data not shown) indicating that the phenotype was growth
phase-independent. Despite the fact that expression of BlaI in trans on plasmid pBlaI did not
fully abolish the increased beta-lactamase activity (see above), the S. aureus Newman blaI
mutant expressing pBlaI showed WT levels for both CRAMP and LL-37 resistance indicating
functional complementation of blaI in terms of cathelicidin susceptibility (Fig 2A and 2B).
Additionally, no differences in cathelicidin killing as compared to the MRSA252 WT strain
were observed for a blaZmutant in this strain background (data not shown) further ensuring
that the cathelicidin susceptibility phenotype of the blaImutant was specific to the blaI gene.
BlaI Promotes Survival of S. aureus in HumanWhole Blood and
Virulence in Murine Infection Models
To establish whether the blaI-mediated cathelicidin resistance could lead to increased survival
of S. aureus in the host, we performed killing assays in human whole blood and compared the
virulence of WT and blaImutant bacteria in murine abscess and septicemia models. As shown
in Fig 3A, the S. aureus Newman blaImutant was killed significantly better by human whole
blood than the WT and complemented strains. In a murine skin abscess model, lesions formed
by WT S. aureusNewman were significantly larger than those created by the blaImutant (Fig
3B), and in murine sepsis models, virulence of the blaImutant was found strongly attenuated
in S. aureusNewman (Fig 3C) and moderately impaired in MRSA252 (Fig 3D). Taken
together, the human whole blood ex vivo and the mouse in vivo data suggested that BlaI con-
tributes to the pathogenic potential of S. aureus.
The Surface Charge of S. aureus Is Not Altered by blaI Inactivation
After establishing that BlaI contributes to cathelicidin resistance, whole blood survival and the
virulence potential of S. aureus, we aimed to determine the mechanism through which BlaI
exerts these actions. A common AMP resistance mechanism among Gram-positive and Gram-
negative bacteria is to reduce their net negative surface charge through cell envelope modifica-
tions in order to repel positively charged AMPs [8]. However, the Newman and MRSA252 WT
and their respective blaImutant strains showed no significant difference in surface charge as
assessed by poly-L-lysine-FITC binding (Fig 4A). A strain pair of S. aureus Sa113 and an
BlaI and S. aureusCathelicidin Resistance
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isogenicmprF negative mutant served as controls, where the mutant strain showed increased
Poly-L-lysine binding as expected from the literature [14].
Hydrophobicity Is Modestly Affected by Inactivation of blaI
Another mechanism by which bacteria resist AMPs is through increased hydrophobicity of
their cell membrane [15]. To test if there was a difference in hydrophobicity between WT and
blaImutant strains, we utilized a version of the microbial adhesion to hydrocarbon assay. We
observed small, though significant, differences in hydrophobicity between the NewmanWT
and blaImutant strains in stationary phase and between both the Newman and MRSA252WT
and their respective blaImutant strains in mid-log phase (Fig 4B and 4C). However, the differ-
ences were differing in direction based on growth phase. As mentioned above, AMP suscepti-
bility differences between WT and blaImutant strains were found to be growth phase-
independent. Thus, it was unlikely that hydrophobicity was playing a major role if any in BlaI-
mediated AMP resistance.
Proteolytic Activity Is Decreased in S. aureus Newman and MRSA252
blaIMutants
Proteolytic cleavage is a third mechanism bacteria utilize to resist AMPs. To test if there were
differing levels of protease activity in the strains, we used skim milk agar plates. As demon-
strated in the representative result in Fig 4D, colonies of the S. aureus NewmanWT strain car-
rying the empty complementation vector pDC123 showed robust zones of clearance around
them demonstrating protease activity. In contrast, the blaImutant with pDC123 did not have
any apparent protease activity on skim milk agar plates (Fig 4D). Since the protease activity
could be restored to WT levels by expression of blaI in trans in the complemented mutant
Fig 2. Effect of blaI on the cathelicidin susceptibility of S. aureus. (A, B) S. aureusNewman and (C, D)
MRSA252WT, blaImutant or complemented mutant strains were incubated with CRAMP or LL-37 and the
numbers of surviving CFUs were determined at the indicated time points. Samples were run in triplicate, and
average CFU/mL values ± SD for one representative experiments of at least two performed for each data set
is shown on a log scale. *, p<0.05; **, p<0.01, ***, p<0.001.
doi:10.1371/journal.pone.0136605.g002
BlaI and S. aureusCathelicidin Resistance
PLOS ONE | DOI:10.1371/journal.pone.0136605 August 25, 2015 5 / 15
strains, the higher proteolytic activity of the WT strain could be attributed to the presence of
functional blaI/BlaI (Fig 4D). MRSA252 WT and blaImutant strains did not show any evident
protease activity on skim milk agar plates (data not shown).
To test if there were differing levels of cathelicidin cleavage between the WT and their
respective blaImutant strains, we incubated overnight cell-free supernatants with CRAMP or
LL-37 for 24 h and subsequently ran the samples on an SDS-PAGE gel. We did not discern any
differences between the NewmanWT and blaImutant strains but did observe a decrease in
CRAMP cleavage by the MRSA252 blaImutant compared to its parental strain (Fig 4E).
Subinhibitory Concentrations of 6-aminopenicillanic (6-APA) Renders
Penicillin-Resistant S. aureusMore Susceptible to Cathelicidin-Mediated
Killing
We hypothesized that the exposure of S. aureus NewmanWT to beta-lactams would force the
bacteria to remove their beta-lactamase repressor BlaI and in consequence would lead to
increased susceptibility to cathelicidin AMPs. To address this possibility, S. aureus Newman
was incubated with a subinhibitory concentration of 6-APA, which is the active core structure
Fig 3. BlaI contributes to survival in human whole blood and virulence in vivo. (A) S. aureusNewman
WT with empty complementation vector pDC123, the blaImutant with pDC123, and the complemented blaI
mutant strain were incubated for 1 h in human whole blood and CFU numbers enumerated. Samples were
run in triplicate and data were plotted as the average percentage ± SD for each strain as compared to the
initial inocula. A representative experiment of three performed is shown. **, p<0.01. (B) CD-1 mice (n = 8)
were injected subcutaneously on one flank with S. aureusNewmanWT and on the opposite flank with blaI
mutant bacteria, and lesion sizes were monitored for 7 days. The lesions for each individual mouse at Day 7
are plotted and the average value indicated. Overall, the blaImutant lesions were significantly smaller
compared to the WT (p<0.04; paired t-test). (C-D) Survival of CD-1 mice (n = 10) after intraperitoneal infection
with (C) 1 x 106 CFU of S. aureusNewmanWT or Newman blaImutant or (D) 6 x 108 CFU of MRSA252 or
MRSA252 blaImutant. Survival was monitored for 3 days. The survival for Newman or MRSA252 blaImutant
strain infected mice was significantly higher than for theWT infected strains as assessed by log-rank (Mantel
Cox) test; the p values are shown in the respective graphs.
doi:10.1371/journal.pone.0136605.g003
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of all penicillins. Subsequently, the killing by LL-37 was tested as compared to untreated cells.
As can be seen in Fig 5, subinhibitory concentrations of 6-APA led to increased beta-lactamase
activity in S. aureus Newman and rendered the bacteria more susceptible to LL-37.
Discussion
It has been established that an increased degree of resistance to human cathelicidin LL-37 is
found in MRSA [16] and that the degree of LL-37 resistance among strains of pathogenic bac-
teria, such as group A streptococci, can correlate to the potential for invasive infection [17].
Thus, the identification and characterization of AMP resistance mechanisms in bacteria with
Fig 4. Potential mechanisms of cathelicidin resistance. (A) Surface charge of S. aureusNewman and
MRSA252 strains was compared by poly-L-lysine binding. The S. aureus strain Sa113 and an isogenicmprF
mutant with increased negative surface charge were used as controls. (B, C) Hydrophobicity was measured
using a modified version of the MATH (microbial adhesion to hydrocarbons) assay. *, p<0.05; **, p<0.01;
***, p<0.001; n.s., not significant. (D) Proteolytic activity of NewmanWT + pDC123, the blaImutant
+ pDC123 and the blaImutant complemented with pBlaI on skim milk agar plates. Clearance zones around
colonies indicate secreted protease activity. (E) Degradation of CRAMP or LL-37 by overnight cell-free
supernatants analyzed by SDS-PAGE.
doi:10.1371/journal.pone.0136605.g004
Fig 5. Pre-incubation with subinhibitory concentrations of the beta-lactam antibiotic 6-APA increases
the beta-lactamase activity and LL-37 susceptibility of S. aureusNewman. Bacteria were incubated for
60 min at 37°C in the absence or presence of 6-APA. For an aliquot of each sample the beta-lactamase
activity was subsequently determined with nitrocefin as test reagent (A). The residual bacteria were
incubated with or without LL-37 for another 60 min and the surviving CFUs were quantified (B). Samples were
run in triplicate and one representative experiment of three performed is shown. ***, p<0.001.
doi:10.1371/journal.pone.0136605.g005
BlaI and S. aureusCathelicidin Resistance
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pathogenic potential is of interest because the responsible genes and gene products could be
promising targets for novel antibacterial agents. Our work described here demonstrates that
BlaI renders S. aureusmore resistant to the cathelicidin AMPs CRAMP and LL-37 as well as to
whole blood killing. Additionally, our mouse challenge studies provide evidence that BlaI con-
tributes to the virulence potential of beta-lactam resistant S. aureus strains in vivo.
It has been shown that MecI and BlaI bind to the same DNA binding motif and have co-reg-
ulatory effects on the expression of beta-lactamase and PBP2a: MecI can repress the BlaI target
gene blaZ and BlaI can repress the MecI target genemecA [18]. With respect to the similarities
between MecI and BlaI, we speculate, that MecI could also contribute to the cathelicidin resis-
tance and virulence potential of MRSA strains. The co-regulatory effects of MecI may also
explain the diminished phenotypes seen in the MRSA252 background, which contains themec
operon, compared to the Newman background, which does not contain themec operon.
Today, more than 95% of methicillin-susceptible S. aureus (MSSA) and MRSA isolates from
human infections are resistant to penicillin [2]. It is commonly accepted that the bacteria
acquired the BlaZ-BlaR1-BlaI-encoding genes through mobile genetic elements as a result of
survival pressure following the introduction of penicillin as an anti-staphylococcal medication
in the early 1940’s. Despite the fact that MRSA is resistant to beta-lactams—including beta-lac-
tams susceptible to BlaZ hydrolysis—via expression of PBP2a (encoded bymecA), the majority
of current, epidemic MRSA clones still express the BlaZ-BlaR1-BlaI-encoding locus [19]. The
experimental observation that blaI contributes to staphylococcal resistance to host innate
immune molecules and virulence extends the number of possible explanations for why so
many MSSA and MRSA isolates harbor and keep the blaZ-blaR1-blaI genes: In addition to the
continuing selection by beta-lactam antibiotics, the beta-lactamase regulatory system also
might contribute to the fitness of S. aureus within the host by modulating the expression of vir-
ulence genes by BlaI. Heterologous expression of the BlaZ-BlaR1-BlaI system in beta-lacta-
mase-negative S. aureus strains would allow to follow-up on this hypothesis.
Our study did not identify the exact mechanism(s) of action of how BlaI contributes to
cathelicidin resistance and virulence in S. aureus Newman and MRSA252. It could not be
attributed to the increased BlaZ beta-lactamase activity in the Newman blaImutant, since the
complemented Newman blaImutant strain showed WT levels of cathelicidin resistance despite
significantly increased BlaZ activity as compared to the parental strain. Hydrophibicity and
surface charge also did not appear to play a role for the cathelicidin susceptibility of the blaI
mutants. Despite the fact that S. aureus NewmanWT and complemented blaImutant strains
had a markedly higher protease activity than the Newman blaImutant on skim milk agar
plates, no difference between the strains was found in terms of their capability to digest catheli-
cidin. From the results, it can be concluded that either the protease concentration in the S.
aureus Newman supernatant was not high enough to observe cathelicidin degradation in the
cell-free assays or a protease-independent mechanism might be responsible for the lower sus-
ceptibility of the WT strain to cathelicidin. In contrast, cathelicidin cleavage might contribute
to the higher resistance of the MRSA252 WT strain to CRAMP. Follow-up studies comparing
the resistance profile of the WT and blaImutant strains in the presence of specific protease
inhibitors would help further evaluate the role of proteases for the observed cathelicidin pheno-
type in S. aureus blaImutants.
We speculate that the transcription factor BlaI can regulate genes beyond blaZ andmecA,
which in turn leads to diminished cathelicidin killing of the bacteria. The above mentioned
striking differences in protease activity between S. aureus NewmanWT and blaImutant on
skim milk agar plates would support the hypothesis of a BlaI regulon that involves genes out-
side of the bla andmec operons. Evidence that regulators controlling beta-lactamase produc-
tion may govern the expression of additional genes was shown forMycobacterium tuberculosis
BlaI and S. aureusCathelicidin Resistance
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[20]. Future studies may wish to conduct gene chip microarrays to identify differences in the
gene expression patterns of S. aureusWT and blaImutants. Moreover, putative BlaI binding
sites in published S. aureus genomes may be found by searching for the conserved DNA motif
TACA/TGTA in the promoter regions of open reading frames.
Finally, we showed that subinhibitory concentrations of 6-APA acid render beta-lactam
resistant S. aureusmore susceptible to innate host defense molecules, which could open an ave-
nue of treatment regimes for difficult to treat S. aureus infections. The addition of beta-lactams
to the treatment regimen in S. aureus infections to inactivate BlaI may render the bacteria
more susceptible to cathelicidin-dependent host defense. Of note, beta-lactam treatment of
MRSA can increase binding and activity of the cationic antibiotic daptomycin [21,22] suggest-
ing exploration of such sensitizing mechanisms could prove a fruitful area for further
investigation.
Materials and Methods
Ethics Statement
The animal experiments were carried out in strict accordance with the recommendations in
the Guide for the Care and Use of Laboratory Animals of the National Institutes of Health. The
Institutional Animal Care and Use Committee of the University of California, San Diego (Ani-
mal Welfare Assurance Number: A3033-01) approved all animal procedures prior to the exper-
imentation. All efforts were made to minimize suffering of animals employed in this study.
Small volumes of blood for in vitro bactericidal assays were collected from healthy human
volunteers under informed written consent through a protocol approved by the University of
California, San Diego (UCSD) Human Research Protection Program IRB (#131002; protocol
name: "Studies of Bacterial Resistance to Whole Blood or Neutrophil Killing”, P.I. V. Nizet)”.
Bacterial Strains and Culture Conditions
The staphylococcal strains used for this study were S. aureus Newman and MRSA252 WT
[5,12]. As a control for the screening of cathelicidin susceptible S. aureusNewman transposon
mutants, an AMP susceptible S. aureusNewman dltAmutant [23] was used. For surface charge
studies, the S. aureus ATCC-35556 (Sa113) WT and an isogenicmprFmutant strain, known to
have an increased negative surface charge compared to the WT strain, served as controls [14].
Tn917 mutants and blaI and blaZmutants were generated as described below, and 5–10 μg/mL
erythromycin (Em) for S. aureus Newman [24] or 10 μg/mL chloramphenicol (Cm) for
MRSA252 were employed for antibiotic selection. For complementation experiments in S.
aureus Newman, 10 μg/mL Cm was used for culture of the WT and blaImutant strains carry-
ing the empty complementation vector pD123 or pDC123 with a copy of blaI (pBlaI). For pro-
duction of knockout and complementation vectors, Escherichia coli strains were used as host
and grown in Luria-Bertani broth (LB); the antibiotic selection employed 100 μg/mL ampicil-
lin, 500 μg/mL Em or 10 μg/mL Cm. The restriction deficient intermediate host strain S. aureus
RN4220 [25] was used to replicate plasmids produced in E. coli before transfer into the staphy-
lococcal target strains.
Preparation of S. aureus Newman Transposon Mutant Library
Random transposon mutagenesis of S. aureus Newman was performed using Tn917 essentially
as described for Group B Streptococcus [13]. Briefly, the temperature sensitive suicide plasmid
pTV1OK, which has a kanamycin (Km) resistance marker in the vector backbone and harbors
Tn917 carrying an Em resistance gene, was introduced via electroporation into S. aureus
BlaI and S. aureusCathelicidin Resistance
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RN4220. Plasmid DNA was isolated and transferred into the target strain S. aureus Newman.
Several transformants were grown overnight in THB with 1 mg/mL Km at 30°C, a temperature
permissive for pTV1OK replication. Overnight cultures were diluted 1/1,000 into THB without
antibiotics, the temperature shifted to a non-permissive temperature (37°C) and incubated
overnight yielding several potential random Tn917 mutant libraries which were stored at -80°C
in THB, 35% glycerol. The randomness of Tn917 transposition in selected libraries was subse-
quently determined. To that aim, serial dilutions of the libraries were plated on Todd Hewitt
agar (THA) plates with 5 μg/ml Em and incubated overnight at 37°C. The chromosomal
Tn917 transposition events were identified in single colonies exhibiting Em resistance. The
DNA of 10 randomly picked colonies per library was digested withHindIII and integration of
Tn917 was probed for by Southern blot analysis using a digoxigenin-labeled transposon spe-
cific probe. The analysis of transposon mutant library #2 demonstrated a random chromo-
somal distribution of Tn917 insertion and a single integrated copy of Tn917 in at least 90% of
the mutant strains (data not shown). For subsequent phenotypic screens, 4,800 transposon
mutants of library #2 were picked, grown up overnight in 100 μl THB with 5 μg/ml Em and
stored in a total of fifty 96-well plates at -80°C in THB + 40% glycerol.
Screen for Cathelicidin Susceptible Transposon Mutants
A 96-well microtiter plate assay was established to screen transposon library #2 for mutants
susceptible to the murine cathelicidin CRAMP. Notably, S. aureus is known to be highly resis-
tant to cathelicidin AMPs in commonly used complex growth media such as THB or tryptic
soy broth (TSB), but more susceptible in carbonate-containing solutions such as RPMI-1640
[26]. First, we showed that S. aureusNewmanWT and the cathelicidin susceptible S. aureus
Newman dltAmutant strain grew well in RPMI-1640, 10% LB medium. The minimal inhibi-
tory concentration [13] of commercially synthesized CRAMP (Genemed Synthesis) in this
medium was determined to be 3 μM for the dltAmutant, a concentration at which the WT
strain was not inhibited. Subsequently, stationary phase cultures of the 4,800 S. aureus New-
man Tn917 mutants were tested for their growth in the presence or absence of 3 μMCRAMP
in order to identify genes that contribute to the cathelicidin resistance of the WT strain. Puta-
tive CRAMP susceptible candidate mutants identified in primary screens were subjected to
additional testing to verify cathelicidin susceptibility. Their growth was compared to that of the
WT strain in THB, and exponential phase mutant bacteria with no growth defect were re-
tested for their cathelicidin susceptibility in CRAMP killing assays as described below.
Identification of Tn917 Insertion Sites
The site of Tn917 insertion in CRAMP susceptible mutants was determined by using the fol-
lowing protocol. In a first PCR, genomic DNA obtained from the mutant strains was subjected
to PCR with a random primer (5'-GGCCACGCGTCGACTAGTACATTACTAGCTACGCC-3')
and the Tn917 specific primer 1st_left_Tn917 (5'-CCATGTTAAACCCATAGATAA-3'). The
resulting amplification products were purified using standard procedures and subjected to a
second and third PCR using the random primer mentioned above and the Tn917 specific
primer 2nd_left_Tn917 (5'-ACACCTGCAATAACCGTTACC-3'). The binding site of
2nd_left_Tn917 is located downstream of 1st_left_Tn917 of the Tn917 sequence and thus was
expected to specifically react with primary PCR products containing parts of the Tn917 and
the disrupted Newman gene sequence. The final PCR products were purified and sequenced at
Eton Bioscience Inc. (San Diego, CA) using the sequencing primer 3rd_left_Tn917 (5'-AGA
GAGATGTCACCGTCAAG-3'). The obtained sequences were compared with published gene
sequences in the GenBank database using the BLAST algorithm. In the transposon mutant
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G2E3, the insertion of Tn917 in blaI was verified by two PCRs using the primer blaI-integ
(5-AGATCTTGTGTTGGGTTATTGAACA-3') in combination with either 1st_left_Tn917 or
2nd_left_Tn917.
Targeted Mutagenesis
Plasmid insertional mutagenesis was performed to inactivate blaI in S. aureus Newman and
MRSA252 as described [24]. For generating the blaImutants, genomic DNA preparations
from Newman and MRSA252 were used as templates. The primers blaI_ko_f_XbaI (5’-GCT
CTAGATGGCCAATAAGCAAGTTGAA-3’) and blaI_ko_r_BamHI (5’-CGGGATCCACTAAT
ATCATTTAAAATGTC-3’) with overhangs constructing XbaI and BamHI restriction sites
into the PCR product were employed to amplify the first 351 bps of blaI by PCR. Please note
that the blaRI gene, upstream of blaI, would be left intact using the described knockout strat-
egy. The PCR products were cloned into pCR2.1-TOPO (Life Technologies, Grand Island, NY)
according to the manufacturer’s instructions and propagated in E. coli. The plasmids were iso-
lated, and the knockout constructs were digested with BamHI/XbaI. For knocking out blaI in
S. aureus Newman, the constructs were then ligated with BamHI/XbaI digested temperature
sensitive suicide vector pHY304, which confers Em resistance. The knockout vectors where
then propagated in E. coli, subsequently transferred into S. aureus RN4220 and finally into the
target strain Newman by electroporation using standard methods. The target strains carrying
the knockout plasmids were grown under Em selection at 30°C, a temperature permissive for
pHY304 replication. The cultures were shifted to a non-permissive temperature to allow only
for survival of mutants with integrated plasmids in the presence of Em. PCR analysis for single
Em resistant colonies was used to confirm the targeted disruption of blaI in S. aureus Newman.
The same cloning strategy was used for generating MRSA252 blaI- and beta-lactamase-defi-
cient blaZmutants. However, since MRSA252 is instrinsically Em resistant, the restriction
enzyme digested PCR products were cloned into the suicide vector pVE6007 [27], which car-
ries a Cm resistance gene, and subsequently utilized to knock out blaI and blaZ as described
above for the pHY304 construct.
Complementation Analysis
For complementation of blaI in trans in S. aureus Newman, blaI plus flanking DNA was PCR
amplified from a Newman genomic DNA preparation using primers blaI_complementa-
tion_f_SphI (5’-CGGCATGCGAAAAGTATGAACTGTATGG-3’) and blaI_complementa-
tion_r_BamHI (5’-CGGGATCCGAGTCAAGCATAGTTTACA-3’); the PCR product was
cloned directionally into the expression vector pDC123 [28] which confers Cm resistance,
yielding plasmid pBlaI. pBlaI was propagated in E. coli, transferred into S. aureus RN4220 and
finally the S. aureus Newman blaImutant as described above. As control strains for compara-
tive functional analyses, the empty expression vector pDC123 was also put into the S. aureus
NewmanWT and blaImutant strains.
Nitrocefin Test
Nitrocefin is a chromogenic cephalosporin used to determine beta-lactamase activity [29].
When cleaved, it changes from yellow to red in color. Bacteria were grown in complex media,
then washed, photometrically adjusted to the desired CFU concentration in phosphate buffer
and then incubated with 50 μg/ml nitrocefin (CalBiochem/EMDMillipore, Billerica, MA) and
incubated at 37°C for 30 min in the dark. The absorbances of the samples at 490 nm (A490)
were read to determine the level of nitrocefin cleavage. Increased absorbance values corre-
sponded to increased beta-lactamase activity.
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Minimum Inhibitory Concentrations for Penicillin and Daptomycin
Penicillin (Sigma-Aldrich, St. Louis, MO) MIC testing was performed by microbroth dilution
in accordance with CLSI guidelines [30]. MICs were performed in triplicate and repeated three
times. Daptomycin MICs were determined by Etest (bioMérieux, Durham, NC) according to
manufacturer’s instructions. An Etest strip for daptomycin was placed on the center of the
plate, and plates were incubated at 37°C overnight.
Cathelicidin Killing Assays
Mid-log or stationary phase bacteria grown in THB or TSB were washed and subsequently
spectrophotometrically adjusted to 107 CFU/ml in Dulbecco’s phosphate-buffered saline
(DPBS) + 10% TSB + 50 mMNaHCO3. 225 μl were added to 25 μl of CRAMP or LL-37 (Syn-
Pep Corporation, Dublin, CA) and incubated at 37°C. At the indicated time points, 25 μl were
removed, diluted in PBS and plated on THA for enumeration of CFU.
HumanWhole Blood Assay
Blood was drawn from healthy donors and 106 CFU of mid-log phase bacteria in 10 μl of DPBS
+ 10% TSB were added to 990 μl heparinized whole blood in siliconized tubes. Tubes were
placed on a rotisserie at 37°C for 1 h, at which point 25 μl were removed, diluted in ddH2O to
lyse blood cells, and plated for enumeration of CFU.
Murine Skin Abscess and Systemic Infection Models
Eight-week-old female CD-1 mice (Charles River Laboratories, Wilmington, MA) were shaved
and treated with Nair for hair removal on the day prior to injection. Mice were injected subcu-
taneously with 5 x 107 CFU of mid-log phase Newman or Newman blaImutant bacteria sus-
pended in 100 μl of DPBS + 0.5 μg/ml cytodex beads (Sigma-Aldrich). Lesion sizes were
monitored for 7 days and their area in mm2 calculated. No unexpected deaths occurred during
the skin infection experiments.
For systemic infection, eight-week-old female CD-1 mice per group were injected intraperi-
toneally with 1.3 x 107 CFU (Newman) or 6 x 108 CFU (MRSA252) of mid-log phase WT or
blaImutant bacteria suspended in 200 μl of DPBS + 5% gastric mucin (MP Biomedicals, Santa
Ana, CA). Survival was monitored every 12 h for 3 d. As a humane end point, mice were imme-
diately euthanized if they were found moribund during the monitoring period.
To minimize animal suffering and distress, all mice were monitored twice a day for lack of
mobility, hunched posture or moribundity caused by the experimental infections. Such animals
were immediately humanely euthanized as described below. Anesthetics were not used during
induction of the experimental infections, since the duration of the subcutaneous and intraperi-
toneal injection procedures were very brief. Pain medications were not used for the experi-
ments since it was not clear how these affect infection outcomes.
Mice in all animal experiments were humanely euthanized in a designated CO2 inhalation
chamber; the gas flow was maintained for at least two minutes after apparent clinical death;
death of these mice was verified by cervical dislocation.
FITC-Labeled Poly-L-Lysine Binding
Poly-L-lysine (PLL) is a positively charged molecule used to measure surface charge. The assay
was modified from a previously described method [31]. Briefly, overnight cultures were washed
twice with HEPES (20 mM, pH 7.25) and suspended to an A578 of 0.3. The bacterial suspension
was incubated with 1 μg/ml FITC-labeled PLL (Sigma-Aldrich) for 15 min at room
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temperature and subsequently washed. By flow cytometry, the degree of PLL binding, which
inversely reflected the relative positive surface charge, was determined. A total of 10,000 events
were recorded and analyzed using a BD FACSCalibur instrument and software (Becton Dickin-
son, Franklin Lakes, NJ).
Hydrophobicity
The hydrophobicity of bacterial cells was tested using a modified version of the MATH (micro-
bial adhesion to hydrocarbons) assay [32]. Stationary phase bacteria were resuspended to A600
= 1.0 in DPBS. 900 μL were added to 300 μl hexadecane in triplicate. Tubes were vortexed for 2
min and subsequently left to stand at room temperature for 35 min to allow separation of
hydrophobic and aqueous layers. 25 μL were subsequently removed from the aqueous layer,
diluted in PBS and plated to allow for enumeration of CFU.
Proteolytic Activity and Cathelicidin Degradation
The S. aureus NewmanWT harboring the complementation vector pDC123, the blaImutant
+ pDC123 and the complemented blaImutant strains were grown in THB, Cm 10 μg/mL,
washed and adjusted to equal CFU concentrations in PBS. Subsequently, 10 μL of the bacterial
suspensions were dropped onto THA skim milk plates containing 10 μg/mL Cm to compare
the proteolytic activities. The agar plates were incubated for 24–72 h at 37°C. Areas of clearance
around the colonies indicated secreted protease activity. Protease activity tests with the
MRSA252 WT and blaImutant strains were carried out using skim milk agar plates without
Cm.
To assess cathelicidin degradation, supernatants from staphylococcal overnight cultures
grown in TSB were filter sterilized through a 0.22 μm syringe-driven filter (EMDMillipore).
18 μl of filtered supernatants were incubated with 2 μl of CRAMP or LL-37 to give a final con-
centration of 16 μMCRAMP or 8 μM LL-37. Samples were incubated at 37°C for 24 h, mixed
with 4x sample buffer and 10x reducing agent (Life Technologies), boiled for 10 min, loaded
onto a 12% Bis-Tris gel (Life Technologies) and run at 120 V in MES running buffer. Gels were
stained with SimplyBlue SafeStain (Life Technologies) and subsequently destained in H2O.
Treatment with 6-Aminopenicillanic Acid (6-APA)
Bacteria were grown to mid-log phase in DPBS + 10% TSB and resuspended to 107 CFU/ml in
the same buffer. Bacteria were incubated alone or in the presence of a subinhibitory dose of
6-APA in siliconized tubes on a rotisserie for 1 h at 37°C. Subsequently, S. aureusNewman bac-
teria were incubated with 24 μM LL-37 or water in a 96-well round bottom plate shaking for 1
h at 37°C. Subsequently, the CFU concentrations were determined as above.
Statistical Analyses
Nitrocefin tests were analyzed using one-way ANOVA with Bonferroni post-test. Cathelicidin
kinetics were compared using repeated measures two-way ANOVA with Bonferroni post-test
except for MRSA252 + CRAMP, which was analysed using Student’s unpaired t-test. The
whole blood assay was analysed using one-way ANOVA with Bonferroni post-test. Lesion sizes
for the murine abscess model were compared using the Student’s paired t-test. The murine
intraperitoneal challenge survival curves were compared using the log-rank (Mantel Cox) test.
Poly-L-lysine-FITC binding was compared using one-way ANOVA. Hydrophobicity was ana-
lyzed using one-way ANOVA (Newman) or Student’s unpaired t-test (MRSA252). All
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statistical tests were performed using GraphPad Prism version 5.0 (GraphPad Software Inc.,
San Diego, CA). P values<0.05 were considered statistically significant.
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